Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- Nucleosomes chromosomal deoxyribonucleases DNA histones H2A H2B H3 H4 octameric cores transcription amino termini acetylation phosphorylation methylation ?-amino lysines acetyltransferases HATs chromatins genes activation deacetylases HDACs catalyzes hydrolytic acetyls sirtuins trichostatins A-insensitive lysyl-deacetylases class III catalyzes deacetylation nicotinamides O-acetyl-ADP-ribose NAD+ human SIRT1 SIRT2 SIRT3 SIRT4 SIRT5 SIRT6 SIRT7 cytoplasmic proteins H4 lysine-16 lysine-40 ?-tubulin a-tubulin alpha-tubulin HDAC6 microtubules mitotic chromosomal hyperpolid cells tissues skeletal muscle heart oligodendroglia brain tumor suppressor gliomas Down-regulation gene chromosomal region diagnostic marker fluorescence-based inhibitors activators p53 Gln-Pro-Lys-Lys(?-acetyl)-AMC recombinant NAD+ fluorescent fluorescence kits assays measures measurement
- Product Overview:
The sirtuins represent a distinct class of trichostatin A-insensitive lysyl-deacetylases (class III HDACs) that catalyze a reaction coupling lysine deacetylation to the formation of nicotinamide and O-acetyl-ADP-ribose. Cayman’s SIRT2 Direct Fluorescent Screening Assay provides a fluorescence-based method for screening SIRT2 inhibitors or activators. The procedure requires only two easy steps, both performed in the same microplate. In the first step, the substrate, which comprises the p53 sequence Gln-Pro-Lys-Lys(?-acetyl)-AMC, is incubated with human recombinant SIRT2 along with its cosubstrate NAD+. Deacetylation sensitizes the substrate such that treatment with the Developer in the second step releases a fluorescent product.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.